慢性乙型肝炎治疗的研究进展

Progress for treatment of chronic hepatitis type B

慢性乙型病毒性肝炎是一个严重威胁人类健康的疾病,呈世界性流行。抗病毒治疗是减少肝硬化、肝癌等严重肝病发生的关键治疗,目前公认有效的抗病毒药物包括干扰素和核苷(酸)类似物。抗病毒药物治疗的持续应答率仅有20%-30%,病毒耐药率高,且停药后容易反弹或复发。那么对CHB的抗病毒治疗时机的把握、药物的选择、治疗的目标、治疗效果的评价及终点的界定就显得尤为重要。

chronic hepatitis B,which is epidemic around the world,is a disease that threatens the health of human bengs. Antiviral therapy is the crucial treatment that minimizes the possibility of serious liver disease happenng such as cirrhosis of liver, hepatocellular carcinoma and so on. At present the generally accepted effective antiviral drugs include interferon and nucleoside analogue. The present situation of antiviral therapy is that the continuous response rate is only from 20 percent to 30 percent,antiviral resistance rate is high and furthermore it is easy to bounce or relapse after the patients stopped the drugs using. Therefore, it appears so important to assure the timing of antiviral treatment,choice of drugs,the aims of treatment,the evaluation of treatment effectiveness and the definition of termination.